glp-1 and satiety Potential mechanisms of weight loss caused by the effects of GLP‐1 GLP-1 Receptor Agonists: From Diabetes

Specific food aversions can develop, often toward fatty, greasy, or very sweet foods

Clinical evidence does not show that GLP-1 agonists directly activate or worsen autoimmune thyroid disease

The association remains largely observational and patient-reported rather than formally quantified in controlled studies

Prescription weight loss medications offer significant benefits for long-term weight management

4G) were highest in the CKD + CG group than in the other groups, higher in the CKD group than the SC and CKD + CG + dulaglutide groups, and were moderately higher in the CKD + CG + dulaglutide group than in the SC group

Diminished immunoreactive gastric inhibitory polypeptide response to a meal newly diagnosed type 1 (insulin-dependent) diabetes J Clin Endocrinol Metab 1983 56 (6): 13061312